You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
"Best Provider" Winner,
2019 Waters Rankings Awards:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Australian regulator approves Endologix's abdominal aortic aneurysm treatment
COVID-19 Pandemic Likely To Cause US Telemedicine Boom
Gauging Supply Chain Risk In Volatile Times
Cannabis: Hashing Out a Budding Industry
IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help
The Australian Therapeutic Goods Administration approved Endologix Inc.'s AFX2 Bifurcated Endograft System for inclusion on the Australian register of therapeutic goods.
The regulator has approved the use of AFX2 for the treatment of abdominal aortic aneurysms.
Endologix CEO John McDermott said the approval in Australia will allow the company to start offering the latest version of the anatomical fixation system to physicians and patients starting in 2017.